Cargando…
Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome
BACKGROUND: Non-alcoholic fatty liver (NAFLD) and its related metabolic syndrome have become major threats to human health, but there is still a need for effective and safe drugs to treat these conditions. Here we aimed to identify potential drug candidates for NAFLD and the underlying molecular mec...
Autores principales: | Tian, Ruifeng, Yang, Jinjie, Wang, Xiaoming, Liu, Shuaiyang, Dong, Ruixiang, Wang, Zhenya, Yang, Zifeng, Zhang, Yingping, Cai, Zhiwei, Yang, Hailong, Hu, Yufeng, She, Zhi-Gang, Li, Hongliang, Zhou, Junjie, Zhang, Xiao-Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024454/ https://www.ncbi.nlm.nih.gov/pubmed/36932412 http://dx.doi.org/10.1186/s13020-023-00729-5 |
Ejemplares similares
-
A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure
por: Wang, Zhenya, et al.
Publicado: (2023) -
The glucotoxicity protecting effect of honokiol in human hepatocytes via directly activating AMPK
por: Liu, Hui, et al.
Publicado: (2022) -
Honokiol attenuates lipotoxicity in hepatocytes via activating SIRT3-AMPK mediated lipophagy
por: Liu, Jingxin, et al.
Publicado: (2021) -
Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013) -
Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
por: Yang, Zifeng, et al.
Publicado: (2023)